Log in

LON:DXRXKainos Group Share Price, Forecast & News

GBX 151.50
0.00 (0.00 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: GBX 151.50
50-Day Range
MA: GBX 140.93
52-Week Range
Now: GBX 151.50
Volume5,495 shs
Average VolumeN/A
Market Capitalization£105.42 million
P/E Ratio252.50
Dividend YieldN/A
Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and technical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation, workshops, diagnostic adboards, conference support, and proficiency testing services; and reimbursement services. The company is based in Belfast, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceuticals: Other



Sales & Book Value

Annual Sales£13.44 million
Cash FlowGBX 16.54 per share
Book ValueGBX 28.90 per share



Market Cap£105.42 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

Kainos Group (LON:DXRX) Frequently Asked Questions

Has Kainos Group been receiving favorable news coverage?

Media stories about DXRX stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kainos Group earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutKainos Group.

Who are some of Kainos Group's key competitors?

Who are Kainos Group's key executives?

Kainos Group's management team includes the following people:
  • Mr. Peter Keeling, CEO & Director
  • Mr. Philip H. White, CFO, Company Sec. & Director
  • Mr. Damian Thornton, Chief Operating Officer
  • Mr. Jordan Clark, Chief Technical Officer
  • Ms. Zarina Bibi, Gen. Counsel

What is Kainos Group's stock symbol?

Kainos Group trades on the London Stock Exchange (LON) under the ticker symbol "DXRX."

How do I buy shares of Kainos Group?

Shares of DXRX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Kainos Group's stock price today?

One share of DXRX stock can currently be purchased for approximately GBX 151.50.

How big of a company is Kainos Group?

Kainos Group has a market capitalization of £105.42 million and generates £13.44 million in revenue each year. Kainos Group employs 111 workers across the globe.

What is Kainos Group's official website?

The official website for Kainos Group is www.diaceutics.com.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.